Affiliation: University of Rome Tor Vergata
- [Interstitial pulmonary fibrosis in chronic HCV hepatitis treated with interferon]C Sarrecchia
Dipartimento di Sanita Pubblica, Universita Tor Vergata, Roma
Recenti Prog Med 92:336-9. 2001..The correlation among interstitial pulmonary fibrosis, HCV infection and interferon treatment is discussed; however in the described case, the pulmonary pathology was correlated to interferon treatment...
- HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAbCesare Sarrecchia
Universita di Roma Tor Vergata, Dipartimento di Sanita Pubblica, Rome, Italy
J Infect Chemother 11:189-91. 2005....
- Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistanceC Sarrecchia
Department of Public Health, University of Rome Tor Vergata, Rome, Italy
Infection 39:367-70. 2011....
- Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapyLaura Ceccarelli
Infectious Disease Unit, Tor Vergata University Hospital, Rome, Italy
J Infect 65:180-3. 2012..Furthermore, it is of outstanding importance to identify alternative markers (e.g. cccDNA, HBV core related antigen, etc.), that could be predictive of HBV reactivation...
- Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigenValeria Cento
Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, 00100 Rome, Italy
J Infect 67:303-12. 2013..Furthermore, due to HBV-RT/HBsAg gene-overlap, they can have an impact on HBsAg-detection and quantification...
- HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitorsValeria Cento
Department of Experimental Medicine and Biochemical Sciences, University of Tor Vergata, Rome, Italy
PLoS ONE 7:e39652. 2012..Because of the extreme genetic variability of hepatitis C virus (HCV), we analyzed whether specific HCV-genotypes are differently prone to develop resistance to linear and macrocyclic protease-inhibitors (PIs)...